A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Incyte Corporation
Incyte Corporation
Eilean Therapeutics
Eilean Therapeutics
Incyte Corporation
Incyte Corporation
Incyte Corporation
Prelude Therapeutics
iOnctura
Incyte Corporation
Hangzhou GluBio Pharmaceutical Co., Ltd.
AbbVie
American Regent, Inc.
Cellenkos, Inc.
AbbVie
Epigenetix, Inc.
Astex Pharmaceuticals, Inc.
Newave Pharmaceutical Inc
AbbVie
Lynk Pharmaceuticals Co., Ltd
Prelude Therapeutics
Taiga Biotechnologies, Inc.
Medigene AG
Novartis
Tarix Pharmaceuticals
Daiichi Sankyo
Eli Lilly and Company
Eli Lilly and Company
Prescient Therapeutics, Ltd.
JW Pharmaceutical
Millennium Pharmaceuticals, Inc.
Exelixis
CASI Pharmaceuticals, Inc.